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oAbstract
Background: Renal ischemia/reperfusion (I/R) injury is commonly seen in kidney
transplantation and affects the allograft survival rates. We aimed to test our
hypothesis that scavenging reactive oxygen species (ROS) with tempol would
protect renal oxygenation and nitric oxide (NO) levels in the acute phase of renal I/R.
Methods: Rats were randomly divided: (1) no I/R, no tempol; (2) no I/R, but with
tempol; (3) I/R without tempol; and (4) I/R with tempol. I/R was induced by 30-min
clamping of the renal artery. Tempol (200 μmol/kg/h/i.v) was administered 15 min
prior to I/R.
Results: I/R without tempol led to a significant decrease in renal oxygen delivery
and microvascular oxygenation. Tempol, however, protected renal oxygenation after
I/R. At R90, the creatinine clearance rate was lower in the I/R-subjected group that
did not receive tempol compared to that in the other groups. I/R injury without
tempol treatment led to a significant increase in tissue malondialdehyde levels and
a significant decrease in tissue NO levels. Tempol administration before I/R could
prevent oxidative stress and altered tissue NO levels.
Conclusions: This underscores that unbalance between oxygen, NO, and ROS forms
an important component of the pathogenesis of I/R-induced AKI and should
therefore be taken into account when designing a prevention/treatment strategy for
renal I/R injury in transplantation.
Keywords: Superoxide dismutase; Tempol; Tempo; Ischemia; Reperfusion; Renal;
Microcirculation; Oxygenation; Nitric oxideBackground
Acute kidney injury (AKI) is a complex clinical complication and is associated with a
high incidence of morbidity and mortality [1, 2]. One of the most common causes of
AKI is renal ischemia/reperfusion (I/R) injury as it can occur in numerous scenarios
such as during surgery and also as a result of shock (low perfusion), resuscitation (normal
or even high perfusion), and renal transplantation [3–5]. Post-transplantation dysfunction
is described as a delayed graft function, and the related pathophysiology of AKI is still in-
completely understood, despite the identification of several mechanisms underlying the2015 Aksu et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
reativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
riginal work is properly credited.
Aksu et al. Intensive Care Medicine Experimental  (2015) 3:21 Page 2 of 10development of AKI. It is clear, however, that instead of a single mechanism being
responsible for its etiology, AKI is associated with an entire orchestra of failing
cellular mechanisms [5–8].
It is well known that reactive oxygen species (ROS) are fundamentally implicated as
primary culprits in the pathophysiology of renal I/R injury and consequent AKI. The excess
generation of ROS and decreases in antioxidant defenses are known to contribute to I/R
injury. Superoxide dismutase (SOD), an ubiquitous intrinsic biological antioxidant, catalyzes
the dismutation of superoxide anions into oxygen and hydrogen peroxide. Tempol
(4-hydroxy-2,2,6,6-tetramethyl piperidinoxyl) is a membrane-permeable, metal-independent
SOD mimetic specific for superoxide anions (O2
−). Several studies have demonstrated that
tempol may reduce renal I/R injury through its free radical scavenging activity [9, 10].
In a series of recent reviews, we have described that our hypothesis that a disturbed bal-
ance between oxygen, nitric oxide (NO), and ROS might form an important component
of the pathogenesis of I/R-induced AKI [11, 12, 8]. In the present study, we aimed to test
whether the proven protective effects of tempol are indeed associated with improved renal
oxygenation and NO levels in a short-term rat model of renal transplantation.Methods
Animals
All experiments in this study were approved by the Institutional Animal Experimentation
Committee of the Academic Medical Center of the University of Amsterdam. Care and
handling of the animals were in accordance with the guidelines for Institutional and Animal
Care and Use Committees. The study has been carried out in accordance with the Declar-
ation of Helsinki. The experiments were performed on 24 Sprague-Dawley rats (Harlan
Netherlands BV, Horst, The Netherlands) with a mean ± SD body weight of 348 ± 21 g.Surgical preparation
All the animals were anesthetized with an intraperitoneal injection of a mixture of 75 mg/
kg ketamine (Nimatek®, Eurovet, Bladel, The Netherlands), 0.5 mg/kg dexmedetomidine
(Dexdomitor, Pfizer Animal Health BV, Capelle aan den IJssel, The Netherlands), and
0.05 mg/kg atropine-sulfate (Centrafarm Pharmaceuticals BV, Etten-Leur, The
Netherlands). After preparing a tracheotomy, the animals were mechanically ventilated
with a FiO2 of 0.4. Body temperature was maintained at 37 ± 0.5 °C during the entire ex-
periment by an external thermal heating pad. Ventilator settings were adjusted to maintain
end-tidal pCO2 between 30 and 35 mmHg and arterial pCO2 between 35 and 40 mmHg.
For drug and fluid administration and hemodynamic monitoring, vessels were cannu-
lated with polyethylene catheters with an outer diameter of 0.9 mm (Braun, Melsungen,
Germany). A catheter in the right carotid artery was connected to a pressure transducer
to monitor mean arterial blood pressure (MAP) and heart rate. The right jugular vein
was cannulated for continuous infusion of Ringer’s lactate (Baxter, Utrecht, The
Netherlands) at a rate of 15 mL/kg/h and maintenance of anesthesia. The right femoral
artery was cannulated for drawing blood samples and the right femoral vein for fluid
resuscitation.
The left kidney was exposed, decapsulated, and immobilized in a Lucite kidney cup
(K. Effenberger, Pfaffingen, Germany) via ~4 cm incision in the left flank in each
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adrenal gland. A perivascular ultrasonic transient time flow probe was placed around
the left renal artery (type 0.7 RB Transonic Systems Inc., Ithaca, NY, USA) and
connected to a flow meter (T206, Transonic Systems Inc., Ithaca, NY, USA) to continu-
ously measure renal blood flow (RBF). An estimation of the renal vascular resistance
(RVR) was made as: RVR (dynes.sec.cm−5) = (MAP/RBF) × 80. The left ureter was
isolated, ligated, and cannulated with a polyethylene catheter for urine collection.
After the surgical preparation, one optical fiber was placed 1 mm above the decapsu-
lated kidney and another optical fiber was placed 1 mm above the renal vein to meas-
ure renal microvascular and venous oxygenation using phosphorimetry (explained in
more detail below). A small piece of aluminum foil was placed on the dorsal side of the
renal vein to prevent contribution of the underlying tissues to the phosphorescence
signal in the venous pO2 measurements. Oxyphor G2, a two-layer glutamate dendrimer
of tetra-(4-carboxy-phenyl) benzoporphyrin (Oxygen Enterprises Ltd., Philadelphia, PA,
USA), was subsequently infused (i.e., 6 mg/kg IV over 5 min), followed by 30 min of
stabilization time. The surgical field was covered with a humidified gauze compress
throughout the entire experiment to prevent drying of the exposed tissues.Experimental protocol
After a stabilization period of 30 min, the animals were randomly divided into four groups
of six: (1) no I/R, no tempol (CTRL); (2) no I/R, but with tempol (TMPL); (3) I/R without
tempol (I/R); and (4) I/R with tempol (I/R + TMPL). Ischemia/reperfusion was induced by
30-min non-destructive clamping of the renal artery. The tempol-treated animals received
200 μmol/kg/h of 4-hydroxy-TEMPO (tempol) intravenously 15 min prior to initiation of
I/R. Measurements were performed up to 90 min post-ischemia, and after the experi-
ments, the kidneys were isolated and renal tissue malondialdehyde (oxidative stress
marker) and nitric oxide levels were measured.Blood variables
Arterial blood samples (0.5 ml) were taken from the femoral artery at baseline (BSLN)
and after 15 and 90 min of reperfusion (R15 and R90, respectively). The blood samples
were replaced by the same volume of Ringer’s lactate. The samples were analyzed for
blood gas values (ABL505 blood gas analyzer; Radiometer, Copenhagen, Denmark),
hemoglobin concentration, and hemoglobin oxygen saturation (OSM3; Radiometer,
Copenhagen, Denmark). Additionally, plasma creatinine and sodium concentrations
were determined in all the samples.Renal microvascular and venous oxygenation
Microvascular oxygen tension in the renal cortex (CμPO2), outer medulla (MμPO2),
and renal venous oxygen tension (PrvO2) were measured by oxygen-dependent quench-
ing of phosphorescence lifetimes of the systemically infused albumin-targeted (and
therefore circulation-confined) phosphorescent dye Oxyphor G2 [13]. Oxyphor G2 has
two excitation peaks (λexcitation1 = 440 nm, λexcitation2 = 632 nm) and one emission peak
(λemission = 800 nm). These optical properties allow (near) simultaneous lifetime
measurements in microcirculation of the kidney cortex and the outer medulla due to
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renal venous PO2 (PrvO2), a mono-wavelength phosphorimeter was used [14]. Oxygen
measurements based on phosphorescence lifetime techniques rely on the principle that
phosphorescence can be quenched by energy transfer to oxygen resulting in shortening
of the phosphorescence lifetime. A linear relationship between reciprocal phosphores-
cence lifetime and oxygen tension (i.e., the Stern-Volmer relation) allows quantitative
measurement of PO2 [15].Renal oxygen delivery and consumption
Arterial oxygen content (AOC) was calculated by (1.31 × hemoglobin × SaO2) + (0.003 ×
PaO2), where SaO2 is the arterial oxygen saturation and PaO2 is the arterial partial pressure
of oxygen. Renal venous oxygen content (RVOC) was calculated as (1.31 × hemoglobin ×
SrvO2) + (0.003 × PrvO2), where SrvO2 is the venous oxygen saturation and PrvO2 is the
renal vein partial pressure of oxygen (measured using phosphorimetry). Renal oxygen
delivery was calculated as DO2 (mL/min) = RBF × AOC. Renal oxygen consumption was
calculated as VO2 (mL/min) = RBF × (AOC – RVOC).Renal function
For analysis of urine volume, creatinine concentration, and sodium (Na+) concentration at the
end of the protocol, urine samples from the left ureter were collected for 10 min. Creatinine
clearance rate (CCR) per gram of renal tissue was calculated with standard formula: CCR
[mL/min] = (UC ×V)/PC, where UC is the urine creatinine concentration,V is the urine vol-
ume per unit time, and PC is the plasma creatinine concentration. Renal sodium reabsorption
(TNa+, [mmol/min]) was calculated as TNa+ = (PNa+ ×CCR)− (UNa+ ×V), where UNa+ is the
urine sodium concentration and PNa+ is the plasma sodium concentration.Renal tissue oxidative stress
Renal tissue malondialdehyde (MDA) levels were determined to assess lipid peroxidation
as a measure of renal oxidative stress. All kidneys were homogenized in cold 5-mM so-
dium phosphate buffer. The homogenates were centrifuged at 12,000g for 15 min at 4 °C,
and supernatants were used for MDA determination. The level of lipid peroxides was
expressed as micromoles of MDA per milligram of protein (Bradford assay).Renal tissue NO levels
NO undergoes a series of reactions in biological tissues leading to the accumulation of the
final products nitrite and nitrate. Thus, the index of the total NO accumulation is the sum
of both nitrite and nitrate levels in the tissue samples. To reduce the nitrate and nitrate
pressnet in the tissue samples to NO, the samples were put in the reducing agent vanadium
(III) chloride (VCl3) in 1 mol/L HCl at 90 °C. The VCl3 reagent converts nitrite, nitrate,
and S-nitroso compounds to NO gas which is guided towards an NO chemiluminescence
signal analyzer (Sievers 280i analyzer, GE Analytical Instruments) allowing the direct detec-
tion of NO [16]. Within the reaction vessel, NO reacted with ozone to generate oxygen
and excited-state NO species, of which the decay is associated with the emission of weak
near-infrared chemiluminescence. This signal is detected by a sensitive photodetector and
converted to millivolts (mV). The area under the curve of the detected chemiluminescence
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available NO in the tested samples. The ratio of tissue NO to tissue protein content was
used for standardization of the NO measurements.Data analysis
Data analysis and presentation were performed using GraphPad Prism (GraphPad Soft-
ware, San Diego, CA, USA). The values are reported as the mean ± SD. Two-way ANOVA
for repeated measurements with a Bonferroni post hoc test were used for comparative
analysis between groups. A p value of <0.05 was considered statistically significant.Results
Systemic and renal hemodynamics and oxygenation
All systemic and renal hemodynamic and oxygenation variables are presented in Tables 1
and 2. MAP and renal VO2 remained stable throughout the entire protocol in all the groups.
Tempol administration in the sham-operated animals (i.e., without I/R) did not affect any of
the systemic and renal hemodynamic and oxygenation variables. I/R without tempol
administration led to a significant decrease in RBF (2.5 ± 0.6 mL/min at R15 and 2.4 ±
0.3 mL/min at R90) and DO2 (1.05 ± 0.28 mL O2/min at R15 and 0.90 ± 0.22 mL O2/min
at R90) and a significant increase in RVR (3298 ± 955 dyn·s·cm−5 at R15 and 3352 ±
426 dyn·s·cm−5 at R90). Tempol administration prior to I/R was able to preserve RBF
(4.0 ± 0.9 mL/min at R15 and 4.1 ± 1.6 mL/min at R90), DO2 (1.61 ± 0.46 mL O2/min at
R15 and 1.75 ± 0.70 mL O2/min at R90), and RVR (1999 ± 471 dyn·s·cm
−5 at R15 and
2200 ± 1046 dyn·s·cm−5 at R90).Renal microvascular oxygenation
Renal microvascular oxygenation in the cortex and medulla decreased quickly during
ischemia but normalized immediately upon reperfusion. However, at R90, microvascu-
lar oxygenation was again significantly decreased in the I/R-subjected group that did
not receive tempol (44 ± 11 mmHg in the cortex and 41 ± 5 mmHg in the medulla)
while this was maintained in the I/R-subjected group that did receive tempol (57 ±
4 mmHg in the cortex and 51 ± 2 mmHg in the medulla).Renal oxidative stress and NO levels
The renal microvascular oxygenation, oxidative stress, and NO levels at the end of the
protocol are presented in Fig. 1. Tempol administration without I/R injury led to a sig-
nificant decrease in tissue MDA levels (1.6 ± 0.17) and I/R injury in the absence of tem-
pol led to a significant increase in tissue MDA levels (3.8 ± 0.9). Tempol administration
before I/R could partially prevent this increase in MDA levels (2.4 ± 0.7). Tissue NO
levels were not affected by tempol administration without I/R injury (240 ± 100), but
were significantly decreased after I/R in the absence of tempol (72 ± 21). Tempol
administration before I/R could completely normalize the tissue NO levels (265 ± 143).
Hence, tempol administration prior to I/R injury reduced renal oxidative stress and
normalized renal oxygenation and tissue NO levels.
Table 1 Mean arterial pressure (MAP), renal blood flow (RBF), renal vascular resistance (RVR), renal
oxygen delivery (DO2), and renal oxygen consumption (VO2) at baseline (Bsln) and after 15 and
90 min of reperfusion (R15 and R90, respectively)
Bsln R15 R90
MAP [mmHg]
CTRL 103 ± 7 103 ± 5 96 ± 6
TMPL 103 ± 8 96 ± 8 93 ± 4
I/R 101 ± 10 96 ± 6 98 ± 6
I/R+TMPL 105 ± 11 95 ± 16 96 ± 16
RBF [mL/min]
CTRL 4.3 ± 1.3 4.1 ± 1.4 3.8 ± 0.5
TMPL 4.2 ± 0.7 3.8 ± 1.0 3.7 ± 1.3
I/R 4.0 ± 0.6 2.5 ± 0.6 CT 2.4 ± 0.3 CT
I/R+TMPL 4.4 ± 1.0 4.0 ± 0.9 I 4.1 ± 1.6 I
RVR [dyn.s.cm-5]
CTRL 2060 ± 583 2143 ± 542 2070 ± 240
TMPL 1989 ± 379 2189 ± 712 2223 ± 733
I/R 2064 ± 414 3298 ± 955 CT 3352 ± 426 CT
I/R+TMPL 1968 ± 454 1999 ± 471 I 2200 ± 1046 I
DO2 [mL O2/min]
CTRL 1.77 ± 0.53 1.65 ± 0.52 1.52 ± 0.22
TMPL 1.75 ± 0.20 1.54 ± 0.18 1.45 ± 0.21
I/R 1.62 ± 0.33 1.05 ± 0.28 CT 0.90 ± 0.22 CT
I/R+TMPL 1.88 ± 0.42 1.61 ± 0.46 I 1.75 ± 0.70 I
VO2 [mL O2/min/g]
CTRL 0.12 ± 0.04 0.11 ± 0.02 0.12 ± 0.02
TMPL 0.13 ± 0.07 0.13 ± 0.03 0.11 ± 0.03
I/R 0.13 ± 0.04 0.10 ± 0.03 0.10 ± 0.03
I/R+TMPL 0.14 ± 0.04 0.13 ± 0.05 0.13 ± 0.04
Cp < 0.05 vs CTRL, Tp < 0.05 vs TMPL, Ip < 0.05 vs I/R
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The renal function variables are presented in Table 3. Tempol administration in the sham-
operated animals (i.e., without I/R) did not affect renal function. I/R without tempol adminis-
tration led to a significant decrease in CCR (0.3 ± 0.1 mL/min at R15) and TNa+ (0.04 ±
0.01 mmol/min at R15). Tempol administration prior to I/R could not prevent these reduc-
tions in CCR (0.4 ± 0.2 mL/min at R15) and TNa+ (0.06 ± 0.03 mmol/min at R15). At R90
these decreases were mostly normalized except for the CCR in the I/R-subjected group that
did not receive tempol.Discussion
In the present study we aimed to test the hypothesis that scavenging ROS using tempol
would not only be associated with reduced renal oxidative stress but also with im-
proved renal oxygenation and NO levels in a short-term rat model of renal I/R. We
have found that I/R was associated with a significant increase in tissue MDA levels
(marker of oxidative stress) and a significant decrease in tissue NO levels. The decrease
Table 2 Microvascular oxygen tension in renal cortex (CμpO2) and medulla (MμpO2) at baseline
(Bsln), at the end of 30 min of ischemia (Isch), and after 15 and 90 min of reperfusion (R15 and
R90, respectively)
Bsln Isch R15 R90
CμpO2
[mmHg]
CTRL 76 ± 2 70 ± 4 70 ± 4 62 ± 7
TMPL 76 ± 3 71 ± 8 73 ± 6 58 ± 6
I/R 79 ± 4 11 ± 4 CT 59 ± 4 44 ± 11 CT
I/R+TMPL 77 ± 6 10 ± 4 CT 66 ± 9 57 ± 4 I
MμpO2
[mmHg]
CTRL 61 ± 5 57 ± 6 54 ± 4 51 ± 4
TMPL 57 ± 9 56 ± 10 55 ± 7 50 ± 7
I/R 59 ± 6 7 ± 1 CT 50 ± 3 C 41 ± 5 CT
I/R+TMPL 59 ± 5 7 ± 1 CT 59 ± 7 I 51 ± 2 I
Cp < 0.05 vs CTRL, Tp < 0.05 vs TMPL, Ip < 0.05 vs I/R
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renal DO2, and renal microvascular oxygenation. These disturbances were associated
with reduced renal function in terms of sodium reabsorption and creatinine clearance.
Pre-ischemic administration of tempol, a known superoxide scavenger, was able to pre-
vent excessive oxidative stress and thereby protect renal tissue NO levels and micro-
vascular oxygenation. Taken together, this led to a preserved renal function after I/R.Fig. 1 Renal oxygenation, oxidative stress, and nitric oxide (NO) levels at the end of the protocol. a Microvascular
oxygen tensions (μpO2) in the renal cortex; b Microvascular oxygen tensions (μpO2) in the renal medulla; c renal
tissue malondialdehyde (MDA) levels normalized to the tissue protein content; and d tissue NO levels normalized
to the tissue protein content. *p < 0.05 vs all other groups; Cp < 0.05 vs the CTRL group; Tp < 0.05 vs
the TMPL group
Table 3 Creatinine clearance rate (CCR) and sodium reabsoption (TNa+) at baseline (Bsln) and after
15 and 90 min of reperfusion (R15 and R90, respectively)
Bsln R15 R90
CCR [mL/min]
CTRL 1.2 ± 0.7 1.3 ± 0.3 1.5 ± 0.7
TMPL 1.1 ± 0.3 1.1 ± 0.3 1.2 ± 0.4
I/R 1.2 ± 0.4 0.3 ± 0.1 CT 0.7 ± 0.4 C
I/R+TMPL 1.4 ± 0.6 0.4 ± 0.2 CT 1.0 ± 0.3
TNa+ [mmol/min]
CTRL 0.18 ± 0.09 0.18 ± 0.09 0.14 ± 0.07
TMPL 0.15 ± 0.04 0.14 ± 0.04 0.13 ± 0.03
I/R 0.16 ± 0.06 0.04 ± 0.01 CT 0.09 ± 0.04
I/R+TMPL 0.20 ± 0.09 0.06 ± 0.03 CT 0.14 ± 0.05
Cp < 0.05 vs CTRL, Tp < 0.05 vs TMPL, Ip < 0.05 vs I/R
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to a reduction in the renal MDA levels normally present in renal tissue, but did not
affect any of the other parameters.
I/R injury is a multi-pathway process in which decreased ROS scavenging and in-
creased ROS generation are particularly important mediators leading to tissue injury
[17, 8]. ROS are created in mitochondria [18], and excess ROS injure the mitochondria,
impair cellular function, and promote apoptosis [19]. It has previously been shown that
antioxidants can decrease cellular and tissue damage by decreasing intracellular ROS
levels and suppressing oxidative stress [20–25]. In this study, we showed that tempol
reduced lipid peroxidation in renal tissue after renal I/R as reflected by decreased tissue
MDA levels [26]. In line, Patel et al. have previously shown that administration of tem-
pone, an unmetabolized form of tempol, reduced I/R-induced injury to peritubular cells
by thereby reducing renal dysfunction [20]. They showed, moreover, that this was with-
out the adverse cardiovascular effects observed when using other nitroxyl radical scav-
enging agents. Noiri et al. also demonstrated that both L-NIL (i.e., a selective inducible
nitric oxide synthase (iNOS) inhibitor) and lecithinized SOD administrations improve
renal function due to scavenging of peroxynitrite and thereby preventing lipid peroxi-
dation and oxidative damage to DNA [27].
In this study, tempol effectively prevented an I/R-induced decrease in tissue NO con-
centration. Decreased NO production via endothelial nitric oxide synthase (eNOS) dur-
ing renal I/R is known to contribute to renal hypoperfusion and renal injury. This has
been supported by studies showing that L-arginine (i.e., a precursor of NO) and NO
donors improve renal function after I/R [21, 28, 29]. On the other hand, also the
administration of iNOS inhibitors has been shown to protect the kidney against I/R in-
jury [30–32, 27]. In the present study, however, the protocol was too short for iNOS
expression to occur. Nonetheless, the administration of tempol did scavenge the excess
ROS generated during the early phase of I/R and thereby prevented the interaction of
eNOS-derived NO and ROS forming peroxynitrite and leaving the NO available for
maintenance of microvascular perfusion. Hence, scavenging ROS has a double benefi-
cial effect.
Our study has, however, some limitations. First, this study was performed in rats and
the effects of tempol could be different in humans. Second, the duration of renal
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and thus long-term effects of I/R and tempol were not studied. Additionally, a longer
duration of ischemia might have caused more severe renal dysfunction. Third, we did
not measure ROS directly but instead measured MDA as a marker of lipid peroxidation
as a result of oxidative stress.
Conclusions
In conclusion, our study demonstrated that scavenging ROS using tempol not only re-
duced renal oxidative stress following I/R but also normalized renal tissue NO levels
and thereby reduced RVR and improves RBF, renal DO2, and renal microvascular oxy-
genation. Taken together, these effects led to a modest (albeit not statistically signifi-
cant) improvement of renal function after I/R. This underscores that a disturbed
balance between oxygen, NO, and ROS forms an important component of the patho-
genesis of I/R-induced AKI and should therefore be taken into account when designing
a prevention/treatment strategy for renal I/R injury in transplantation.
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